ABL Diagnostics specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.7% of net sales.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	€2.500	-3.10%	3,173
05/08/26	€2.580	+2.38%	7,728
04/08/26	€2.520	+2.44%	7,705
03/08/26	€2.460	+1.65%	1,966
31/07/26	€2.420	0.00%	3,241

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 16:55:00 06/08/2026 BST			5-day change	1st Jan Change
2.500 ^EUR	-3.10%		+1.63%	-16.67%

07-23	French Court OKs ABL Diagnostics' Industrial Plan to Acquire Texcell	MT
07-22	ABL Diagnostics Société anonyme agreed to acquire Assets and Business Operations from Texcell SA for ?0.78 million.	CI

Market Cap	40.17M 46.29M 37.6M 34.41M 64.86M 4.4B 65.84M 440M 173M 2.21B 174M 170M 7.34B	P/E 2024	123x	P/E 2025	50x
Enterprise Value	41.11M 47.36M 38.47M 35.2M 66.37M 4.51B 67.37M 450M 177M 2.26B 178M 174M 7.51B	EV / Sales 2024	7,098,474x	EV / Sales 2025	6,185,843x
Free-Float	6.2%	Yield 2024	2.03%	Yield 2025	3.67%

07-23	French Court OKs ABL Diagnostics' Industrial Plan to Acquire Texcell	MT
07-22	ABL Diagnostics Société anonyme agreed to acquire Assets and Business Operations from Texcell SA for ?0.78 million.	CI
07-02	Abl Diagnostics Société Anonyme Approves Dividend Distribution for Fiscal Year 2025, Payable on July 7, 2026	CI
06-12	Abl Diagnostics Sa and Cdl Pharma Secure Multi-Year International Contract of Up to Eur 2.7 Million Through 2031	CI
06-12	ABL Diagnostics Signs Multi-year Contract to Provide Clinical Trial Services	MT
06-12	ABL Diagnostics Secures Multi-Year Contract with CDL Pharma
06-10	ABL Diagnostics Offers to Buy Texcell	MT
06-05	ABL divests block of ABL Diagnostics shares
06-01	ABL Diagnostics Société anonyme Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026	CI
05-18	ABL Diagnostics Société anonyme Proposes Dividend for the Financial Year Ended December 31, 2025, Payable on July 7, 2026	CI
05-06	ABL Diagnostics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Abl Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its Vela Product Line in A Targeted Segment of the French Market	CI
01/10/25	ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2025	CI

07-29	ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL	BU
07-27	ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital	BU
07-23	ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations	BU
07-22	ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL	BU
07-15	ABL Diagnostics Informed that its Reference Shareholder ABL Has Crossed Below the 95% Threshold	BU

ABL Diagnostics Share Price

Stocks

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Valuation: ABL Diagnostics

Chart: ABL Diagnostics

Latest news : ABL Diagnostics

Press Releases: ABL Diagnostics

News in other languages: ABL Diagnostics

Quotes and Performance

Course Extremes

Managers and Directors: ABL Diagnostics

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

07-29	ABL Diagnostics : Cession d'un nouveau bloc d'actions par son actionnaire principal ABL
07-27	ABL Diagnostics annonce la signature d'un avenant au contrat d'Equity Line et de prêt de titres entre son actionnaire principal ABL SA (Luxembourg) et Alumni Capital
07-23	ABL Diagnostics désignée par le Tribunal de commerce d'Évry pour la reprise des activités de TEXCELL
07-22	ABL Diagnostics : Cession d'un nouveau bloc d'actions par son actionnaire principal ABL
07-15	L'actionnaire de référence d'ABL Diagnostics allège ses positions

1 day	-3.10%
1 week	+1.63%
Current month	+3.31%
1 month	-6.02%
3 months	+12.61%
6 months	-19.35%
Current year	-16.67%

1 week	2.38	2.74
1 month	2.18	2.74
Current year	2.12	5
1 year	2.12	5
3 years	2.12	9.7
5 years	1.99	26
10 years	1.28	26

Director	Title	Age	Since
Noemie Sadoun CHM	Chairman	-	-
Laure Raffaelli BRD	Director/Board Member	-	-
Deborah Szafir BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/07/26	Advanced Biological Laboratories SA	Sell	Company	-65,616	0.4072%
06/07/26	Advanced Biological Laboratories SA	Sell	Company	-62,308	0.3867%
13/02/26	Advanced Biological Laboratories SA	Sell	Company	128,026	0.7945%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABL DIAGNOSTICS	-3.10%	+1.63%	-44.44%	-71.59%	47.87M
ABBOTT LABORATORIES	+2.13%	-0.04%	-17.39%	+0.29%	183B
MEDTRONIC PLC	-0.08%	-1.85%	-4.18%	+2.24%	110B
CENCORA, INC.	+2.46%	+2.01%	+11.17%	+75.37%	61.72B
HOYA CORPORATION	-1.64%	+7.20%	+39.25%	+56.58%	54.98B
BECTON, DICKINSON AND COMPANY	+3.76%	+5.15%	+0.10%	-34.61%	47.02B
MEDLINE INC.	-5.88%	-13.90%	-	-	32.16B
DEXCOM, INC.	+0.44%	+10.49%	+10.02%	-31.01%	31.19B
WEST PHARMACEUTICAL SERVICES, INC.	-0.69%	+3.30%	+45.94%	-7.06%	24.7B
STERIS PLC	-0.40%	-1.30%	+3.53%	+2.55%	22.68B
Average	-0.30%	+1.75%	+4.89%	-0.80%	56.75B
Weighted average by Cap.	+0.74%	+0.19%	+1.37%	+9.99%

	2024	2025
Net sales	5.87 6.76 5.49 5.03 9.48 643.26 9.62 64.31 25.22 322.41 25.39 24.83 1.07K	7.97 9.18 7.45 6.82 12.86 873 13.05 87.27 34.23 437.56 34.45 33.7 1.45K
Net income	285K 329K 267K 244K 460K 31.25M 467K 3.12M 1.23M 15.66M 1.23M 1.21M 52.07M	987K 1.14M 923K 845K 1.59M 108M 1.62M 10.81M 4.24M 54.2M 4.27M 4.17M 180M
Net Debt	2.02M 2.33M 1.89M 1.73M 3.27M 222M 3.32M 22.17M 8.7M 111M 8.75M 8.56M 370M	933K 1.07M 873K 799K 1.51M 102M 1.53M 10.22M 4.01M 51.23M 4.03M 3.95M 170M